SCHEMBL430473

SCHEMBL430473

COc1ccc2c(ccn2S(=O)(=O)c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 1.00
POLB P06746 1/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
MEN1 O00255 2/20 0.80
KMT2A Q03164 2/20 0.80
HDAC1 Q13547 3/20 0.66
HDAC6 Q9UBN7 2/20 0.66
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
HPGD P15428 1/20 0.60
TSHR P16473 1/20 0.60
HTT P42858 1/20 0.60
FABP4 P15090 2/20 0.59
HDAC3 O15379 1/20 0.57
HDAC4 P56524 1/20 0.57
HDAC7 Q8WUI4 1/20 0.57
HDAC2 Q92769 1/20 0.57
HDAC10 Q969S8 1/20 0.57
HDAC11 Q96DB2 1/20 0.57
HDAC8 Q9BY41 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL949712 0.91 HTR6 (0.84) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL10345778 0.89 MEN1 (1.00) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL29559974 0.89 MEN1 (1.00) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL946548 0.87 HTR6 (0.78) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL31159555 0.86 HTR6 (0.76) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL949160 0.86 HTR6 (0.76) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL945665 0.86 HTR6 (0.76) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL5915283 0.86 HTR6 (0.76) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL31159358 0.85 HTR6 (0.74) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL31159375 0.85 HDAC1 (0.77) HTR6POLBL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155674-B1 AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LTD (IN) 2011-06-22 EP claimed
CN-115677722-A Compounds targeting p53 mutants 北京加科思新药研发有限公司 2023-02-03 CN disclosed
EP-3233797-B1 MAP4K4 (HGK) INHIBITORS Sri int inc (US) 2019-05-08 EP disclosed
US-10000451-B2 MAP4K4 (HGK) inhibitors SRI INTERNATIONAL (US) 2018-06-19 US disclosed
US-20170320824-A1 MAP4K4 (HGK) Inhibitors SRI INTERNATIONAL (US) 2017-11-09 US disclosed
EP-3233797-A1 MAP4K4 (HGK) Inhibitors SRI International Inc. (US) 2017-10-25 EP disclosed
WO-2016114816-A1 MAP4K4 (HGK) Inhibitors SRI INTERNATIONAL (US) 2016-07-21 WO disclosed
CN-105732464-A Method for producing indole compound in large scale 杏国新药股份有限公司 2016-07-06 CN disclosed
US-20120022121-A1 INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-01-26 US disclosed
US-20120022121-A1 INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-01-26 US disclosed
WO-2008136017-A1 AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2008-11-13 WO disclosed
US-7307099-B2 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-11 US disclosed
US-7307099-B2 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-11 US disclosed
US-7307099-B2 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-11 US disclosed
US-20060100265-A1 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-05-11 US disclosed
US-20030158216-A1 2-acyl indole derivatives and their use as antitumor agents BAXTER ONCOLOGY GMBH 2003-08-21 US disclosed
US-20020091124-A1 2-acyl indole derivatives and their use as antitumor agents BECKERS THOMAS (DE) 2002-07-11 US disclosed
US-5079363-A From an alkoxypyridine and an indole derivative, antitumor and antileukemia agents SANOFI (FR) 1992-01-07 US disclosed
EP-0155214-B1 2-SULFAMOYL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE MERCK & CO. INC. (US) 1990-03-14 EP disclosed
US-4840963-A FOR GLAUCOMA MERCK & CO., INC. (US) 1989-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100265-A1 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents TXNRD1, TXNRD3, TXNRD2 HTR6 1460/4885POLB 1698/4885L3MBTL1 1346/4885
US-20120022121-A1 INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR TUBB, TUBB3, TUBB1 HTR6 592/4885POLB 1458/4885L3MBTL1 1167/4885
US-20030158216-A1 2-acyl indole derivatives and their use as antitumor agents IDO1, IDO2, INMT HTR6 563/4885POLB 3573/4885L3MBTL1 3305/4885
US-20170320824-A1 MAP4K4 (HGK) Inhibitors MAP4K4, MAP4K2, MAP4K3 HTR6 4239/4885POLB 2808/4885L3MBTL1 2987/4885
US-20020091124-A1 2-acyl indole derivatives and their use as antitumor agents IDO1, IDO2, INMT HTR6 563/4885POLB 3573/4885L3MBTL1 3305/4885
US-10000451-B2 MAP4K4 (HGK) inhibitors MAP4K4, MAP4K2, MAP4K3 HTR6 4239/4885POLB 2808/4885L3MBTL1 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.